14 recruiting. 14 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Recruiting 14 |
| Phase 2 | 1 | Recruiting 1 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis TQH3906 capsules, Deucravacitinib tablets 6 mg, TQH3906 Capsules placebo - Psoriasis | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 400 | 2026-09-02 | 2026-09-09 |
| Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis Zasocitinib - Psoriatic Arthritis | Phase 3 | Recruiting | Takeda | 1182 | 2026-03-11 | 2026-09-09 |
| Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis Ponesimod - Moderate-to-severe Chronic Plaque Psoriasis | Phase 3 | Recruiting | Vanda Pharmaceuticals | 300 | 2026-02-17 | 2026-09-22 |
| Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis Cosmetic patch containing urea applicated daily for 3 months, Placebo patch application - Nail Psoriasis, Nail Damage | Phase 3 | Recruiting | Wooshin Labottach Co., Ltd. | 72 | 2026-02-01 | 2026-01-26 |
| Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III) Total coumarin (TC) cream, Vehicle cream - Psoriasis Vulgaris, Topical Administration | Phase 3 | Recruiting | Psoriasis Research Institute of Guangzhou | 300 | 2026-02-01 | 2026-02-23 |
| A Study of Picankibart in Patients With Active Psoriatic Arthritis Placebo, Picankibart - Psoriatic Arthritis | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 222 | 2025-12-18 | 2026-03-20 |
| A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis IBI112, placebo - Psoriasis | Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 104 | 2025-12-03 | 2025-12-22 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis Deucravacitinib, Placebo - Plaque Psoriasis | Phase 3 | Recruiting | Bristol-Myers Squibb | 366 | 2025-12-03 | 2026-10-27 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis Bimekizumab, Placebo - Palmoplantar Pustulosis | Phase 3 | Recruiting | UCB Biopharma SRL | 320 | 2025-11-14 | 2026-08-27 |
| Effect of Semaglutide in Patients With Psoriasis and Obesity semaglutide - Psoriasis (PsO), Obesity and Overweight | Phase 3 | Recruiting | The University of Hong Kong | 14 | 2025-03-20 | 2025-05-13 |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines Zasocitinib, Active Comparator, Placebo - Psoriatic Arthritis | Phase 3 | Recruiting | Takeda | 1088 | 2025-03-03 | 2026-10-14 |
| A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants Guselkumab - Crohns Disease, Colitis, Ulcerative | Phase 3 | Recruiting | Janssen Research & Development, LLC | 196 | 2024-10-29 | 2026-11-03 |
| A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab Adalimumab, Risankizumab - Juvenile Psoriatic Arthritis | Phase 3 | Recruiting | AbbVie | 40 | 2024-07-08 | 2026-09-01 |
| A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis Deucravacitinib, Placebo matching deucravacitinib - Plaque Psoriasis | Phase 3 | Recruiting | Bristol-Myers Squibb | 153 | 2021-03-23 | 2026-10-26 |
Arthritis, Psoriatic (5) · Arthritis, Juvenile (2) · Aggressive Periodontitis (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Exanthema (1) · Mycoses (1) · Obesity (1) · Overweight (1) · Pruritus (1)
Skin Diseases (14) · Skin Diseases, Papulosquamous (14) · Skin and Connective Tissue Diseases (14) · Arthritis (5) · Bone Diseases (5) · Joint Diseases (5) · Musculoskeletal Diseases (5) · Spinal Diseases (5) · Spondylarthritis (5) · Spondylarthropathies (5) · Spondylitis (5) · Autoimmune Diseases (2) · Connective Tissue Diseases (2) · Immune System Diseases (2)
deucravacitinib (3) · Adalimumab (1) · bimekizumab (1) · guselkumab (1) · ponesimod (1) · risankizumab (1) · semaglutide (1)
Bristol-Myers Squibb (2) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (2) · Takeda (2) · AbbVie (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · Janssen Research & Development, LLC (1) · Psoriasis Research Institute of Guangzhou (1) · The University of Hong Kong (1) · UCB Biopharma SRL (1) · Vanda Pharmaceuticals (1) · Wooshin Labottach Co., Ltd. (1)
United States (8) · China (7) · Germany (7) · Poland (7) · Spain (7) · Italy (6) · Australia (4) · Canada (4) · France (4) · Hungary (4) · South Korea (4) · United Kingdom (4) · Argentina (3) · Belgium (3) · Brazil (3)
Jiang Yang, MSc, PhD (1) · Liping Yang, MD (1) · Man Ho Martin Chung (1) · Sharon A Glick, MD (1)
2023 (3), 2025 (1)